Natural History of Human Epidermal Growth Factor Receptor 2-Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical Practice.
Carsten SchröderCraig Gower-PageIrmarie Reyes-RiveraArisha PatelRichard PriceShiraj SenJessica DaviesEmily H CastellanosJeremy SniderXiaobo BaiVirginia A FisherShivani K MhatrePublished in: JCO clinical cancer informatics (2022)
This study showed considerable treatment heterogeneity and poor outcomes among patients with treatment-refractory mCRC, emphasizing a substantial unmet therapeutic need.